InflaRx announced two management appointments. Jordan Zwick has been promoted to Chief Strategy Officer, effective immediately. Jordan Zwick has served as head of business development and corporate strategy. With today’s announcement, he will assume additional direct leadership responsibilities in the US operations and finance organization. He has over a decade of finance, marketing and corporate development experience. As part of the healthcare marketing team at Medtronic, he launched a cardiac remote monitoring device in the acute care setting. Jordan next joined the business development team at Salix Pharmaceuticals, working on a wide range of transactions, including the $14.5B acquisition of Salix by Valeant Pharmaceuticals (now Bausch Health Companies) in 2015.